InterVenn demonstrates power of its GlycoVision platform
InterVenn Biosciences has presented new data generated by the company’s novel, proprietary biomarker discovery platform, GlycoVision. The software analysed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and...